Press-release for stocks for bmy

symbols : Bmy

save search

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| 0.0% | O: 1.06% H: 0.0% C: 0.0%
opdivo trial plus

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab)
Published: 2023-12-05 (Crawled : 16:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| Email alert Add to watchlist
drug opdivo review food application

Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
Published: 2023-11-28 (Crawled : 20:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| 1.55% | O: 0.06% H: 0.55% C: -0.27%
RNA | $8.04 1.39% 1.37% 850K

Health Technology

| 25.32% | O: 25.32% H: 3.63% C: -8.29%
expansion collaboration technology cardiovascular platform

Locally Advanced Pancreatic Cancer Market Report 2023-2028: Recent Advancements in Immunotherapy Inject New Hope into LAPC Market
Published: 2023-11-21 (Crawled : 23:00) - prnewswire.com
AZNCF | $125.75 8.15% 2.6K

Health Technology

| 1.87% | O: 0.36% H: 0.0% C: -0.05%
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| 2.68% | O: 0.56% H: 1.53% C: 1.37%
AZN | News | $63.5 -0.14% -0.14% 6.2M

Health Technology

| 0.34% | O: -0.89% H: 0.33% C: -0.16%
report hope cancer pancreatic immunotherapy market

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Published: 2023-11-20 (Crawled : 13:00) - biospace.com/
TSVT | $2.65 12.77% 11.32% 2.1M

| -0.46% | O: -12.96% H: 1.06% C: -7.45%
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -2.74% | O: -4.69% H: 2.85% C: 0.25%
fda review update therapy

FDA Roundup: November 17, 2023
Published: 2023-11-17 (Crawled : 22:00) - prnewswire.com
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| Email alert Add to watchlist
fda

HIV Drugs Market to Reach $51.1 Billion, Globally, by 2032 at 4.5% CAGR: Allied Market Research
Published: 2023-11-17 (Crawled : 16:00) - prnewswire.com
JNJ | News | $155.4 -0.78% -0.02% 6.4M

Health Technology

| 6.03% | O: 0.78% H: 0.0% C: 0.0%
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -2.08% | O: 0.67% H: 0.0% C: 0.0%
ABBV | News | $147.97 1.09% 0.05% 7.2M

Health Technology

| 4.82% | O: 0.01% H: 0.0% C: 0.0%
GILD | $78.03 -1.68% -1.7% 8.2M

Health Technology

| 5.3% | O: -0.13% H: 0.0% C: 0.0%
reach research hiv market

Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research
Published: 2023-11-10 (Crawled : 15:00) - prnewswire.com
PFE | News A | $28.63 -0.56% 0.0% 35M

Health Technology

| -6.88% | O: -4.83% H: 0.0% C: 0.0%
JNJ | News | $155.4 -0.78% -0.02% 6.4M

Health Technology

| 5.67% | O: -1.24% H: 0.0% C: 0.0%
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -5.13% | O: -3.68% H: 0.0% C: 0.0%
ABBV | News | $147.97 1.09% 0.05% 7.2M

Health Technology

| 5.0% | O: 0.44% H: 0.0% C: 0.0%
AZN | News | $63.5 -0.14% -0.14% 6.2M

Health Technology

| -1.02% | O: -2.88% H: 0.0% C: 0.0%
report research market

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -5.13% | O: -3.68% H: 0.0% C: 0.0%
MRTX | $56.64 -0.02% -0.02% 2.3M

Health Technology

| 0.87% | O: -0.11% H: 0.0% C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics

Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
Published: 2023-11-08 (Crawled : 20:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -5.81% | O: -0.62% H: 0.11% C: -0.19%
research collaboration

HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS
Published: 2023-11-08 (Crawled : 13:00) - prnewswire.com
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -5.81% | O: -0.62% H: 0.11% C: -0.19%
STIM | $1.8 -4.76% -5.0% 55K

Health Technology

| 42.34% | O: 5.11% H: 0.0% C: 0.0%
HRMY | $31.07 -3.09% -3.19% 780K

Health Technology

| 29.29% | O: -2.78% H: 0.59% C: -1.72%

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-06 (Crawled : 15:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -3.36% | O: 3.16% H: 0.77% C: -0.66%
MRTX | $56.64 -0.02% -0.02% 2.3M

Health Technology

| 1.83% | O: 0.75% H: 0.59% C: 0.27%
therapeutics financial results

Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -3.36% | O: 3.16% H: 0.77% C: -0.66%
al102 drug tumors pharmaceuticals designation

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -3.84% | O: -1.84% H: 1.08% C: 0.61%
MRTX | $56.64 -0.02% -0.02% 2.3M

Health Technology

| 1.65% | O: 0.2% H: 0.43% C: -0.38%
KURA | $11.27 1.81% 1.77% 800K

Health Technology

| 28.57% | O: -4.76% H: 6.0% C: 5.25%
ko-2806 collaboration therapeutics agreement

Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
Published: 2023-10-31 (Crawled : 00:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -3.73% | O: -0.65% H: 0.0% C: 0.0%

AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Published: 2023-10-31 (Crawled : 11:00) - prnewswire.com
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -3.73% | O: -0.65% H: 0.0% C: 0.0%
XNCR | $20.2 4.88% 4.65% 500K

Health Technology

| 7.75% | O: -0.46% H: 0.0% C: 0.0%
SNY | News | $46.06 0.17% 0.17% 1.9M

Health Technology

| 4.21% | O: 2.61% H: 0.0% C: 0.0%
REGN | $849.57 1.65% 1.63% 560K

Health Technology

| 5.33% | O: -0.51% H: 0.0% C: 0.0%
BGNE J | $182.01 -1.16% -1.18% 180K

Health Technology

| 0.93% | O: 1.38% H: 0.0% C: 0.0%
AMGN S | $271.33 0.74% 0.73% 2M

Health Technology

| 2.32% | O: -3.22% H: 0.0% C: 0.0%
financial results

Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News | $80.35 1.18% -0.03% 5.3M

Finance

| 14.72% | O: 0.83% H: 0.0% C: 0.0%
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -3.73% | O: -0.65% H: 0.0% C: 0.0%
MRTX | $56.64 -0.02% -0.02% 2.3M

Health Technology

| 2.33% | O: 0.46% H: 0.0% C: 0.0%

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
BMY P | $50.16 0.56% 0.0% 14M

Health Technology

| -2.43% | O: 1.35% H: 0.0% C: 0.0%
KPTI | News | $0.8353 -1.83% -1.87% 750K

Health Technology

| 0.38% | O: 2.92% H: 6.08% C: -3.35%
collaboration trial

Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | $3.76 1.62% 2.39% 18K

Finance